ArticleCancer control : journal of the Moffitt Cancer Center
Survival and Pathological Outcomes of Neoadjuvant Chemoimmunotherapy Followed by Surgery in Locally Advanced Oral Squamous Cell Carcinoma.
Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Metabolic syndrome confers a higher risk of oral cancer: a meta-analysis.Frontiers in oncology · 2026Pooled it
- Performance of Machine Learning Models for Prognosis Prediction in Oral Cavity Squamous Cell Carcinoma: A Systematic Review.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionThe prognosis of advanced oral squamous cell carcinoma (OSCC) remains poor, with a 5-year survival rate below 50%. While immune checkpoint inhibitors have improved outcomes in recurrent or metastatic head and neck squamous cell carcinoma, the efficacy of preoperative chemoimmunotherapy for locally advanced OSCC remains under investigation. This study aimed to evaluate pathological responses and survival outcomes in OSCC patients receiving neoadjuvant chemoimmunotherapy followed by surgery.MethodsIn this retrospective cohort study, 30 patients with stage III-IV OSCC were treated with one of two induction regimens: toripalimab plus gemcitabine and cisplatin, or tislelizumab with nab-paclitaxel, cisplatin, and low-dose radiotherapy. All patients underwent radical resection after two cycles. Pathological response was assessed based on residual viable tumor (RVT) proportion. Radiologic response was evaluated per RECIST 1.1. Survival analysis was performed using Kaplan-Meier methods.ResultsThe pathological complete response (pCR) and major pathological response (MPR) rates at the primary site were both 30.0%. Achieving a radiologic partial response was significantly associated with achieving an MPR (P=0.018). With a median follow-up of 28.5 months, the 3-year overall survival (OS) and disease-free survival (DFS) rates were 80.9% and 65.0%. Patients achieving a pPR or better had significantly improved OS (P=0.007) and DFS (P=0.023). Lymph node metastasis, particularly ≥3 positive nodes, was strongly associated with poor survival (P<0.001). A stromal fibroblast proportion ≥70% correlated with better OS (P=0.023).ConclusionNeoadjuvant chemoimmunotherapy followed by surgery yields promising pathological responses and survival outcomes in locally advanced OSCC. The degree of pathological response and lymph node status are critical prognostic factors. Notably, pCR does not universally guarantee favorable outcomes, underscoring the need for vigilant postoperative monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.